Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 20;19(3):221-226.
doi: 10.17305/bjbms.2018.3950.

How latent viruses cause breast cancer: An explanation based on the microcompetition model

Hanan Polansky  1 , Hava Schwab
Affiliations
Review

How latent viruses cause breast cancer: An explanation based on the microcompetition model

Hanan Polansky et al. Bosn J Basic Med Sci. .

Abstract

Most breast cancer cases show a decrease in the concentration of the breast cancer type 1 susceptibility protein (BRCA1). However, only a small portion of these cases have a mutated BRCA1 gene. Although many attempts have been made to identify the reason for the decrease in BRCA1 concentration in sporadic, non-heritable breast cancer cases, the cause is still unknown. In this review, we use the Microcompetition Model to explain how certain latent viruses, which are frequently detected in breast cancer tumors, can decrease the expression of the BRCA1 gene and cause the development of breast tumors.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
The process by which external and internal events lead to breast cancer by way of GABP dysregulation at the BRCA1 promoter. External/internal events cause A) increased latent virus copy number; B) decreased GABP•CBP/p300 binding at BRCA1 promoter; C) decreased BRCA1 gene expression and BRCA1 protein; D) development of breast cancer. GABP: GA-binding protein; BRCA1: Breast cancer type 1 susceptibility protein.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Romagnolo AP, Romagnolo DF, Selmin OI. BRCA1 as target for breast cancer prevention and therapy. Anticancer Agents Med Chem. 2015;15(1):4–14. https://doi.org/10.2174/1871520614666141020153543. - PubMed
    1. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet. 1995;9(4):444–50. https://doi.org/10.1038/ng0495-444. - PubMed
    1. Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res. 2003;5(1):45–52. https://doi.org/10.1186/bcr557. - PMC - PubMed
    1. Skol AD, Sasaki MM, Onel K. The genetics of breast cancer risk in the post-genome era:Thoughts on study design to move past BRCA and towards clinical relevance. Breast Cancer Res. 2016;18(1):99. https://doi.org/10.1186/s13058-016-0759-4. - PMC - PubMed
    1. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 2006;25(43):5898–905. https://doi.org/10.1038/sj.onc.1209879. - PubMed